EAN 2021

COVID-19

First evidence of brainstem involvement in COVID-19

Presented By

Dr Tommaso Bocci, University of Milan, Italy

Conference

EAN 2021

18 August, 2021 10:20

Cognitive/behavioural alterations persistent after COVID-19

Presented By

Prof. Federica Agosta, Vita-Salute San Raffaele University, Italy

Conference

EAN 2021

18 August, 2021 10:10

Neural base of persistent hyposmia after COVID-19

Presented By

Dr Matteo Pardini, University of Genoa, Italy

Conference

EAN 2021

18 August, 2021 10:00

Neurological symptoms and complications of COVID-19 affect outcomes

Presented By

Dr Nina Kleineberg, University Hospital Cologne, Germany

Conference

EAN 2021

18 August, 2021 09:50

Cerebrovascular Disease

Cognitive Impairment and Dementia

Severe outcomes of COVID-19 in patients with dementia

Presented By

Dr Agathe Vrillon, Hôpital Lariboisière Fernand-Widal, France

Conference

EAN 2021

18 August, 2021 10:27

Hypertension pathology visible in white matter lesion volume

Conference

EAN 2021

18 August, 2021 10:15

Promising diagnostic accuracy of plasma GFAP

Presented By

Dr Tandis Parvizi, Medical University of Vienna, Austria

Conference

EAN 2021

18 August, 2021 10:10

Sex modulates effect of cognitive reserve on subjective cognitive decline

Presented By

Dr Giulia Giacomucci, University of Florence, Italy

Conference

EAN 2021

18 August, 2021 10:05

Hypersensitivity to uncertainty in subjective cognitive decline

Presented By

Dr Bahaaeddin Attaallah, University of Oxford, United Kingdom

Conference

EAN 2021

18 August, 2021 10:00

Epilepsy

Minimally invasive device to detect focal seizure activity

Presented By

Prof. Mark Cook, University of Melbourne, Australia

Conference

EAN 2021

18 August, 2021 10:18

Long-term effectiveness of ANT-DBS in epilepsy confirmed

Trial

MORE

Conference

EAN 2021

18 August, 2021 10:16

Good safety and efficacy of cenobamate for focal seizures

Trial

C013, C017, C021

Conference

EAN 2021

18 August, 2021 10:10

Prenatal valproate exposure increases risk of adverse neurodevelopmental outcome

Trial

SCAN-AED

Conference

EAN 2021

18 August, 2021 10:05

‘Mozart effect’ in epilepsy: why Mozart tops Haydn

Presented By

Prof. Ivan Rektor, Masaryk University, Czech Republic

Conference

EAN 2021

18 August, 2021 10:00

Migraine and Headache

Factors associated with decreased migraine attack risk

Presented By

Prof. Christian Wöber, Medical University of Vienna, Austria

Conference

EAN 2021

18 August, 2021 10:59

Eptinezumab shows acute benefits during migraine attack

Trial

Phase 3, RELIEF

Conference

EAN 2021

18 August, 2021 10:58

Erenumab superior to topiramate for migraine treatment

Trial

Phase 4, HER-MES

Conference

EAN 2021

18 August, 2021 10:57

Pregnant migraine patients at higher risk of complications

Presented By

Dr Nirit Lev, Rabin Medical Center, Israel

Conference

EAN 2021

18 August, 2021 10:53

Occipital nerve stimulation in drug-resistant cluster headache

Presented By

Dr Javier Membrilla, University Hospital La Paz, Spain

Conference

EAN 2021

18 August, 2021 10:51

Rhythmicity in primary headache disorders

Presented By

Dr Christoph Schankin, University Hospital of Bern, Switzerland

Conference

EAN 2021

18 August, 2021 10:50

Multiple Sclerosis and NMOSD

Typing behaviour to remotely monitor clinical MS status

Presented By

Dr Ka-Hoo Lam, Amsterdam UMC, the Netherlands

Conference

EAN 2021

18 August, 2021 10:37

Machine-learning method accurately classifies patients with MS

18 August, 2021 10:36

Positive results from ublituximab versus teriflunomide

Trial

Phase 3, ULTIMATE I, ULTIMATE II

Conference

EAN 2021

18 August, 2021 10:35

Alemtuzumab in treatment-naïve patients with aggressive MS

Presented By

Dr Lucia Moiola, IRCCS San Raffaele Hospital, Italy

Conference

EAN 2021

18 August, 2021 10:33

No higher early MS relapse frequency after stopping ponesimod

Presented By

Prof. Ludwig Kappos, University of Basel, Switzerland

Trial

Phase 3, OPTIMUM

Conference

EAN 2021

18 August, 2021 10:32

Satralizumab efficacious in AQP4-IgG-positive patients with NMOSD

Trial

Phase 3, SAkuraSky, SAkuraStar

Conference

EAN 2021

18 August, 2021 10:30

Good long-term safety and efficacy of inebilizumab in NMOSD

Presented By

Prof. Bruce Cree, University of California San Francisco, CA, USA

Trial

Phase 3, N-MOmentum

Conference

EAN 2021

18 August, 2021 10:28

Neuromuscular Disorders

Parkinson’s Disease

Effect of prasinezumab on motor features in early PD

Trial

Phase 2, PASADENA

Conference

EAN 2021

18 August, 2021 11:36

Levodopa-carbidopa intestinal gel in patients with advanced PD

Presented By

Dr József Szász, University of Târgu Mures, Romania

Trial

COSMOS

Conference

EAN 2021

18 August, 2021 11:32

Safinamide improves non-motor symptoms in PD

Trial

SAFINONMOTOR

Conference

EAN 2021

18 August, 2021 11:31

New Frontier – Navigated Transcranial Ultrasound